AAV-based delivery is advancing therapeutic innovation in two clinically important organ systems

As gene therapy continues to evolve, adeno-associated virus, or AAV, has emerged as one of the most important delivery platforms for treating both inherited and acquired diseases. Among the many target organs being explored, the liver and the eye have become two of the most clinically significant areas for AAV-based gene therapy. Each offers distinct biological advantages: the liver is a central metabolic organ that can efficiently produce secreted therapeutic proteins, while the eye is a small, accessible, and relatively compartmentalized organ that is well suited for localized gene delivery.

AAV vectors have already contributed to approved gene therapies in both ophthalmology and hematology, while many additional programs are being developed for liver, retinal, and other ocular indications. These advances highlight the growing potential of AAV to deliver durable therapeutic benefit, while also underscoring the need to address challenges such as immune response, dose optimization, tissue specificity, manufacturing scalability, and long-term safety.

AAV Applications in Liver-Directed Gene Therapy

The liver is one of the most important target organs for in vivo gene therapy. It performs essential functions in metabolism, detoxification, protein synthesis, lipid regulation, and energy balance. Because hepatocytes can produce and secrete therapeutic proteins into circulation, liver-directed AAV gene therapy is particularly attractive for disorders caused by deficiency of circulating proteins or metabolic enzymes.

One of the most successful examples of liver-directed AAV gene therapy is hemophilia. In hemophilia B, AAV vectors can deliver a functional F9 gene to hepatocytes, enabling liver cells to produce factor IX. In hemophilia A, AAV vectors can deliver a functional F8 expression cassette to support factor VIII production. These approaches are designed to reduce bleeding risk and decrease dependence on repeated clotting factor replacement therapy.

Beyond hemophilia, liver-directed AAV approaches are being explored for inherited metabolic disorders, lysosomal storage diseases, urea cycle disorders, familial hypercholesterolemia, and other genetic conditions involving liver function or secreted proteins. In these applications, AAV can be used to introduce a functional gene, restore deficient protein activity, or support long-term therapeutic expression after a single administration.

However, liver-directed AAV therapy also presents important technical and clinical challenges. Systemic delivery often requires high vector doses, which can increase the risk of immune-mediated liver inflammation or other dose-related toxicities. Pre-existing neutralizing antibodies to AAV may limit patient eligibility. In addition, long-term expression in growing pediatric patients may be affected by hepatocyte turnover and liver growth, because AAV genomes generally remain episomal rather than integrating into the host genome.

AAV Applications in Ocular Gene Therapy

The eye has become one of the most successful and intensively studied target organs for AAV gene therapy. Its small size, accessibility, immune-privileged features, and advanced imaging capabilities make it especially suitable for localized gene delivery and precise clinical monitoring. AAV vectors can be administered through routes such as subretinal or intravitreal injection, depending on the target cell type and disease mechanism.

A major milestone in ocular gene therapy was the approval of voretigene neparvovec-rzyl for patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. This therapy uses an AAV2 vector to deliver a functional RPE65 gene to retinal pigment epithelial cells, helping restore part of the visual cycle in eligible patients with sufficient viable retinal cells.

AAV-based ocular gene therapy is also being studied for other inherited retinal diseases, including retinitis pigmentosa, achromatopsia, choroideremia, X-linked retinoschisis, Leber congenital amaurosis caused by other genes, and Stargardt disease. For these conditions, the goal may be gene replacement, gene silencing, gene editing support, or delivery of neuroprotective factors.

In acquired ocular diseases, AAV vectors are being explored as a way to provide sustained intraocular expression of therapeutic proteins. For example, in neovascular age-related macular degeneration, AAV-based approaches may reduce the need for frequent anti-VEGF injections by enabling local production of anti-angiogenic proteins. While this strategy is promising, many programs remain investigational and must demonstrate durable efficacy and acceptable safety compared with established treatment options.

Shared Opportunities and Challenges

AAV gene therapy in the liver and eye demonstrates the versatility of the platform, but these two organ systems also reveal different development challenges. Liver-directed therapy often requires systemic administration and careful control of immune and dose-related safety risks. Ocular therapy can use localized delivery, but it must address surgical delivery complexity, retinal cell targeting, inflammation, and disease-stage dependency.

Important considerations across both fields include:

• Capsid selection: Different AAV serotypes and engineered capsids show different tissue tropism, transduction efficiency, and immune profiles.
• Promoter design: Tissue-specific or cell-type-specific promoters can improve expression precision and reduce off-target activity.
• Dose optimization: The therapeutic window must balance sufficient expression with acceptable safety.
• Immune response: Pre-existing antibodies, capsid-specific T-cell responses, and local or systemic inflammation can affect efficacy and durability.
• Manufacturing quality: High-purity, well-characterized AAV vectors are essential for clinical translation, especially for systemic high-dose applications.
• Long-term durability: Sustained expression must be evaluated over time, particularly in pediatric, progressive, or degenerative diseases.

Future Outlook

The future of AAV therapy for liver and ocular diseases will likely be shaped by next-generation capsids, improved regulatory elements, more efficient manufacturing platforms, and more precise analytical methods. In the liver, engineered capsids may help lower effective doses, improve hepatocyte targeting, and reduce immune-related risks. In the eye, improved capsids may enable broader retinal transduction, more effective intravitreal delivery, and better targeting of specific retinal cell populations.

At the same time, advances in vector genome design, expression cassette optimization, and potency testing will help improve the predictability and consistency of AAV-based therapies. As clinical experience grows, developers will be better positioned to match vector design, route of administration, dose, and patient selection to the biology of each disease.

Conclusion

AAV has opened new therapeutic possibilities for both liver and ocular diseases. In the liver, AAV vectors can transform hepatocytes into long-term producers of therapeutic proteins or enzymes. In the eye, AAV enables localized gene delivery to retinal and ocular tissues, supporting treatment strategies for inherited retinal diseases and potentially reducing treatment burden in acquired ocular disorders.

Although important challenges remain, continued progress in AAV capsid engineering, vector design, manufacturing, and clinical development is expanding the potential of gene therapy. With careful optimization and rigorous validation, AAV-based therapies may provide more durable and precise treatment options for patients with liver and eye diseases.

How PackGene Supports AAV Gene Therapy Research for Liver and Ocular Applications

PackGene provides integrated AAV solutions to support liver-directed and ocular gene therapy research, including vector design, plasmid construction, AAV production, purification, serotype selection, capsid evaluation, and analytical testing. For liver applications, PackGene can support projects requiring hepatocyte-targeted expression, systemic delivery considerations, and scalable AAV production. For ocular applications, PackGene can help researchers design vectors for retinal or ocular cell targeting, localized delivery studies, and disease-specific expression strategies.

By combining customized AAV vector design, scalable production workflows, and quality-focused analytical characterization, PackGene helps researchers and developers generate fit-for-purpose AAV vectors for discovery, preclinical, and translational gene therapy programs.